Neutropenic sepsis leading to multi-organ failure due to capecitabine toxicity
AI-generated summary
Mrs L, a 52-year-old woman with T2N0M0 rectal cancer, died from neutropenic sepsis and multi-organ failure secondary to severe capecitabine toxicity on 31 October 2018. She commenced neoadjuvant chemotherapy with capecitabine on 17 October 2018 and developed severe mucositis, diarrhoea, and signs of toxicity by 26 October. The antidote uridine triacetate (Vistogard) was not considered until 28 October 2018, with administration delayed until 29 October (3.5 days after drug cessation; ideally within 96 hours). Key clinical lessons include: recognising early capecitabine toxicity signs, lack of pre-treatment DPD enzyme deficiency screening, delayed consideration and administration of the specific antidote, and communication failures between institutions. Earlier recognition and antidote administration would likely have improved survival. The case highlights the need for routine DPD testing before fluoropyrimidine chemotherapy and improved access to Vistogard in Australia.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes. Report an inaccuracy.
Specialties
oncologyradiation oncologycolorectal surgeryintensive careemergency medicineENT surgery
Capecitabine toxicity from undetected DPD enzyme deficiency
Delayed recognition of capecitabine toxicity
Delay in consideration and administration of uridine triacetate antidote
Lack of pre-treatment testing for DPD deficiency
Limited availability of uridine triacetate in Australia
Initial misdiagnosis of throat symptoms as allergic reaction to mouthwash
Lack of communication between Royal Melbourne Hospital ED and Peter MacCallum Cancer Centre
After-hours staff unfamiliar with process for accessing Vistogard
Coroner's recommendations
PMCC and MOGA make a submission to the Medical Services Advisory Committee to consider the feasibility of funding DPYD testing for all patients prior to commencement of fluoropyrimidines in Australia and to determine the support required to implement a DPYD testing program to remove the major barrier of cost to testing and provide oncologists and patients the choice to undertake DPYD testing when clinically indicated
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. Some material may have been redacted or restricted by court order or privacy requirements. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction — report an inaccuracy here.